stockrowEdgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Return on assets
Edgewise Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was 85.4%, up 117.7 percentage points from fiscal 2025 (−32.3%). Over the past ten years it has ranged from −32.4% (fiscal 2024) to −20.6% (fiscal 2021); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −32.3% | 0.08 |
| FY2024 | −32.4% | (4.04) |
| FY2023 | −28.3% | (7.59) |
| FY2022 | −20.7% | (0.18) |
| FY2021 | −20.6% | 5.55 |
| FY2020 | −26.1% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 6.68% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| EWTX Edgewise Therapeutics, Inc. | −36.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −41.5% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)